Aripiprazole is a next-generation antipsychotic with a unique mechanism of action, which is indicated for the treatment of schizophrenia and has been extensively studied for the management of acute mania. Two trials have been recently completed with aripiprazole for the treatment of psychiatric symptoms associated with dementia, in Europe and the U.S. The first was a community-based study, and the second was a nursing home-based study. Efficacy, safety and tolerability data from these trials will be presented, and outcome measures of value to clinicians and health care consumers will be discussed.
Back to S108 Atypical Antipsychotic Drugs for the Treatment of Psychiatric Symptoms of Dementia: A New Look at Meaningful Outcomes
Back to Satellite Symposia
Back to The Eleventh International Congress